Latest News about Gene Therapy
Recent news which mentions Gene Therapy
From Benzinga
Braeden Lichti - Investing in Precision Medicine to Yield New Treatments for Neurodegenerative Diseases
November 18, 2021
From PRLog
Bluebird Bio To Withdraw Marketing Of Skysona Gene Therapy In Europe
October 21, 2021
Tickers
BLUE
From Benzinga
Sio Gene Shares Gain As Genetic Nerve Cell Disorder Gene Therapy Trial Shows Encouraging Action
October 21, 2021
Tickers
SIOX
From Benzinga
From Benzinga
4D Molecular To Test Its Wet AMD Gene Therapy In Patients
October 06, 2021
Tickers
FDMT
From Benzinga
Adverum's Single Dose Wet AMD Gene Therapy Shows Robust Two Year Durability, Safety
October 04, 2021
Tickers
ADVM
From Benzinga
Perceptive Advisors-Backed SPAC To Acquire Amicus's Gene Therapy Business
September 29, 2021
From Benzinga
Kids Suffer Adverse Reactions In Applied Genetic's Color Blindness Gene Therapy Trial
September 24, 2021
Tickers
AGTC
From Benzinga
Verve Therapeutics' Gene-Editing Therapy Shows Encouraging Preclinical Action In Cardiovascular Disease
September 23, 2021
Tickers
VERV
From Benzinga
Solid Biosciences Stock Gains After Duchenne Dystrophy Gene Therapy Data
September 23, 2021
Tickers
SLDB
From Benzinga
Bluebird Bio Files US Application For β-thalassemia Gene Therapy
September 22, 2021
Tickers
BLUE
From Benzinga
Novartis Adds Vision Loss Gene Therapy Program Via Arctos Acquisition
September 21, 2021
Tickers
NVS
From Benzinga
Intellia To Test CRISPR-Engineered TCR-T Cell Candidate In Acute Myeloid Leukemia Patients
September 16, 2021
Tickers
NTLA
From Benzinga
Astellas' Gene Therapy Trial Hit With Another Death, FDA Slaps Clinical Hold
September 14, 2021
From Benzinga
AbbVie, RegenXBio Ink $1.75B Retinal Gene Therapy Collaboration
September 13, 2021
From Benzinga
Decibel Therapeutics' Hearing Loss Gene Therapy Receives FDA Orphan Drug Tag
September 09, 2021
Tickers
DBTX
From Benzinga
Roche's Spark Therapeutics, NeuExcell Join Forces To Develop Huntington's Disease Gene Therapy
September 07, 2021
From Benzinga
FDA Slaps Clinical Hold on BioMarin's Gene Therapy For Genetic Metabolism Disorder
September 07, 2021
Tickers
BMRN
From Benzinga
See Why Astellas Stopped Dosing In Neuromuscular Disease Gene Therapy Trial
September 01, 2021
From Benzinga
Bluebird Bio's Shares Drop To 52-Week Low After Another Gene Therapy Trial Placed On FDA Hold
August 09, 2021
Tickers
BLUE
From Benzinga
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.